Altre lingue Celltrion, Inc.

Azioni

A068270

KR7068270008

Biotecnologia

Prezzo di chiusura Korea S.E. Altri mercati azionari 06/02/2026			Variaz. 5gg	Var. 1 gen.
220.000,00 ^KRW	+1,15%		+4,76%	+21,55%

05/02	CVS Health elimina i trattamenti per le malattie ossee di Amgen e Lilly da alcune liste di farmaci (5 febbraio)	RE
30/01	Celltrion lancia Aptozma, farmaco per le malattie autoimmuni, in Europa	MT

Altre lingue

05/02	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)
05/02	Celltrion : Reports Record-High Annual Revenue of KRW 4.1625Tn and Operating Profit of KRW 1.1685Tn in 2025… Signaling Continued Strong Growth Backed by High-Margin Newer Portfolio
30/01	Bourse : les midcaps au pouvoir à Paris, Sandisk flambe, Adidas assure, Swatch déçoit, mais…
30/01	Les premiers seront les derniers, mais pas sûr
30/01	Celltrion Launches Autoimmune Drug Aptozma in Europe
14/01	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference
08/01	Celltrion And Sandoz Launch Their Aflibercept Biosimilars In Europe
06/01	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance
06/01	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
02/01	Health Care Up on Anti-Obesity Drug Sales Outlook - Health Care Roundup
02/01	Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).
02/01	Celltrion Shares Rally on U.S. Contract, Earnings Outlook
01/01	Celltrion Inc U.S. unit Celltrion USA signs production contract with Eli Lilly worth 473 million USD
22/12	Samsung Biologics to buy US drug production facility from GSK for $280 million
18/12	Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector
15/12	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers
11/12	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.
11/12	Celltrion, Inc. announces Annual dividend
03/12	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?
28/11	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)
26/11	Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)
19/11	Celltrion to invest up to $478 million to expand US factory in response to tariffs
18/11	Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg
18/11	Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab
14/11	Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Articoli MarketScreener Analisi MarketScreener Idee di trading

Altre lingue Celltrion, Inc.

Azioni

A068270

KR7068270008

Biotecnologia

Altre lingue

Filtri